*   AUTISM  STUDY   *

               C A L L    F O R    P A R T I C I P A N T S

 The A.D.D. Treatment Center Is Sponsoring

 a Replication Study of  

Assessment-Guided Neurofeedback for Autistic Spectrum Disorder  Assessment Guided Neurofeedback for Autistic Spectrum Disorders, R. Coben and I. Padolsky, Journal of Neurotherapy Vol. 11(1)  Summer, 2007  

Recently Published in the Journal of Neurotherapy

Click to view

 We Are Exploring the Benefits of Neurofeedback Therapy with Autistic Children

  

  Who will be conducting this study?

Ø      Gary Schummer, Ph.D., a licensed Psychologist (PSY11860) and clinical Director of 

       the ADD Treatment Centers, Torrance, will be the Principle Investigator (PI) and will 

       be making all protocol decisions for the study

Ø      Jeffrey Wilson , Ph.D., a licensed Psychologist (PSY11860) and clinical Director of 

       the ADD Treatment Centers, Mission Viejo office

Ø      Karin Zimmermann, Ph.D., a licensed Psychologist (PSY13071) will be administering

      the diagnostic and Neuropsychological testing

Ø      Jack Johnstone, Ph.D., Associate Researcher, Department of Psychology, U.C.L.A.

      and C.E.O. of  Q-Metrx, Inc. and Valley Sleep Center will process and analyze all 

      QEEG (Brainmapping) data

Ø      The QuietMind Foundation, Inc, as an Institutional Review Board will provide ethical  

       and critical oversight to the study

 

Evaluation and Testing Provided:

§         Quantitative EEG, also called “Brain Mapping” (~2 hours)

§         Autism Diagnostic Observation Scale (ADOS) and Autism Diagnostic

     Interview (ADI-R)

§         Selected Neuropsychological tests, parent and teacher rating scales  

Therapy Provided:    Neurofeedback  

 

    About Participating In The Study:  

Ø      This study is sponsored by A.D.D. Treatment Centers and Q-Metrx, Inc.

Ø      Enrollment is underway and   initial interviews begin on or before March 1, 2008

Ø      44 participants will be randomly assigned to ether; 1) a “first treatment” group, or

      2) a delayed treatment or “wait-list" control group

Ø      The "first treatment” group begins therapy soon after enrollment and

      completion of testing

Ø      The “wait-list” group will be tested along with the "first treatment” group but will

       wait 10 after weeks, test again, and then begin therapy

Ø      Both groups will be tested a final time after completing the therapy

Ø      20 visits of Neurofeedback therapy will be provided in our offices twice a week

     for ten weeks   

Ø      After enrollment a diagnostic interview will be conducted by one of our  site 

      coordinators. The child and at least one parent or guardian must be present  

Ø      Status meetings with parent(s) and site coordinator are held at regular intervals

Ø      There can be no breaks or vacations during the 10 weeks of Therapy

Ø      Privacy will be protected at all times

Ø      A positive change is expected but can not be guaranteed

Ø      The paper is expected to be published in an Autism journal

 

About Neurofeedback Therapy…

 

    …a non-invasive treatment using no medication

    …has no known negative side-effects

    …can result in better attention and cognitive abilities

    …may improve speech and socialization skills

    …has demonstrated improvements in 10 weeks or less

 

              ALL PARTICIPANTS CHOSEN TO BE IN THIS STUDY…

   …are between 8 and 16½ years old

   …have Autism as a primary diagnosis

   …never had Neurofeedback therapy before

   …are not taking prescription medication at time of enrollment

   …will receive the treatment (no placebo or “sham” treatment)

   …can come to Torrance or Mission Viejo for testing and therapy

    

 

FINANCIAL INFORMATION

This study has no grant money

Participants will pay $1,820 to offset basic costs

Participants will save from $7,800 to $11,700 off regular prices

Payment must be received at time of initial evaluation

Refunds are  prorated upon withdrawal from study

 

 

FOR MORE INFORMATION OR TO ENROLL 

   CALL

 

(310) 378-0547